ArticleCancer causes & control : CCC2021
Predictors of five-year survival among patients with hepatocellular carcinoma in the United States: an analysis of SEER-Medicare.
Article in Cancer causes & control : CCC, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Hepatocellular Carcinoma Survival in People With and Without HIV in the United States, 2001-2019.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Review
- Non-viral hepatocellular carcinoma masquerading as a liver abscess: a case report highlighting a diagnostic challenge.International journal of surgery case reports · 2026Article
- Quantification of DNA Methylation for Diagnosis and Monitoring of Hepatocellular Carcinoma.Journal of the American College of Surgeons · 2026Article
- Comparison of different machine learning methods in the prediction of early recurrence in HCC patients with Gd-EOB-DTPA-MRI.Abdominal radiology (New York) · 2025Article
- Survival Outcomes in Hepatocellular Carcinoma: Experience from a Multidisciplinary Committee in Ecuador.Life (Basel, Switzerland) · 2025Article
- The association between stage migration and overall survival after radiation-based therapies in patients with hepatocellular carcinoma.JHEP reports : innovation in hepatology · 2025Article
- Identification of Patients with Early-Stage Hepatocellular Carcinoma Benefiting from Neoadjuvant Chemotherapy-A SEER-Based Study.Journal of gastrointestinal cancer · 2025Article
- Real-World Effectiveness of All-Oral Direct-Acting Antivirals in Patients With Hepatitis C Virus-Related HCC.Clinical pharmacology and therapeutics · 2025Article
- A Network Phenotyping Strategy approach in a Turkish HCC Dataset and Comparison of Patients Selected for Transplant and those who were not.Journal of Inonu Liver Transplantation Institute · 2025Article
- Development and validation of a dynamic prognostic nomogram for conditional survival in hepatocellular carcinoma: an analysis from the Korea Liver Cancer Registry.Scientific reports · 2025Article
- Cost-effectiveness of an outreach program for HCC screening in patients with cirrhosis: a microsimulation modeling study.EClinicalMedicine · 2025Article
- Biomarker Panels Associated with Diagnosis and Overall Survival in Hepatocellular Carcinoma Revealed from Protein-Protein and mRNA-miRNA Interaction Networks.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- What can claims data tell us about risk factors and survival of patients with hepatocellular carcinoma? Insights from a German population-based study.Frontiers in oncology · 2025Article
- Integrating T-cell inflammation features for prognosis in hepatocellular carcinoma: a novel predictive model.Journal of gastrointestinal oncology · 2024Article
- Cost-Effectiveness of a Biomarker-Based Screening Strategy for Hepatocellular Carcinoma in Patients with Cirrhosis.Liver cancer · 2024Article
- Article
- Survival Outcomes Among Patients With Hepatocellular Carcinoma in a Large Integrated US Health System.JAMA network open · 2024Article
- Patient Experience of Hepatocellular Carcinoma and Their Treatment Goals: An International Qualitative Study and Patient Journey Map.Advances in therapy · 2024Article
- PNPLA3, Obesity, and Heavy Alcohol Use in Cirrhosis Patients May Exert a Synergistic Increase Hepatocellular Carcinoma Risk.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundMost patients with hepatocellular carcinoma (HCC) are ≥ 65 years old at diagnosis and ~ 20% present with disease amenable to curative intent surgical therapy. The aim of this study was to examine whether treatment, the demographic variables, and clinical factors could predict 5-year survival among HCC patients.
methodsWe included patients, 66 years or older, diagnosed with a first primary HCC from 1994 through 2007 in the SEER-Medicare database, and followed up until death or 31 December 2012. Curative intent treatment was defined as liver transplantation, surgery resection, or ablation. We estimated odds ratios (OR) and 95% confidence intervals (CI) for associations with 5-year survival using logistic regression.
resultsWe identified 10,826 patients with HCC with mean age 75.3 (standard deviation, 6.4) years. Most were male (62.2%) and non-Hispanic white (59.7%). Overall, only 8.1% of patients were alive 5 years post-HCC diagnosis date. Among all patients that survived ≥ 5 years, 69.8% received potentially curative treatment. Conversely, patients who received potentially curative treatment represented only 15.7% of patients who survived < 5 years. Curative intent treatment was the strongest predictor for surviving ≥ 5 years (vs. none/palliative treatment; adjusted OR 8.12, 95% CI 6.90-9.64). While stage at diagnosis and comorbidities were also independently associated with ≥ 5-year survival in HCC patients, these factors did not improve discrimination between short- and long-term survivors.
conclusionsCurative intent treatment was the strongest predictor for survival ≥ 5 years among HCC patients. Given the limited availability of liver transplant and limited eligibility for surgical resection, finding curative intent HCC therapies remain critically important.
Indexed as
Identifiers
33394207What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.